Telaprevir: 1500mg/day p.o., 12weeks Pegylated interferon alpha 2b: 1.5mcg/kg/week i.s., 24weeks Ribavirin: Body weight
Sponsors
Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine
Conditions
Chronic hepatitis C
Unknown Phase
Non-inferiority study of telaprevir dose reduction regimen on telaprevir with pegylated interferon and ribavirin therapy for treatment-naive patients with chronic hepatitis C genotype 1; prospective randomized controlled, multicenter trial
Active, not recruitingJPRN-UMIN000007313
Start: 2012-03-01Target: 280Updated: 2026-06-29
Non-inferiority study of telaprevir dose reduction regimen on telaprevir with pegylated interferon and ribavirin therapy for treatment-experienced patients with chronic hepatitis C genotype 1; prospective randomized controlled, multicenter trial
Active, not recruitingJPRN-UMIN000007330
Start: 2012-03-01Target: 280Updated: 2026-06-29